TEVA vs WST
Teva Pharmaceutical Industries Limited vs West Pharmaceutical Services — AI-powered side-by-side comparison
TEVA
Teva Pharmaceutical Industries Limited
55
Watch
VS
WST
West Pharmaceutical Services
74
Buy
| Metric | TEVA | WST |
|---|
| AI Score |
55
|
74
|
| Price |
$36.49
|
$351.74
|
| P/E Ratio |
57.19×
|
44.65×
|
| ROE |
17.8%
|
15.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
52.5%
|
36.8%
|
| Debt / Equity |
2.16×
|
0.10×
|
| Dividend Yield |
0.0%
|
0.3%
|
| RSI (14) |
77.8
|
58.0
|
| Beta |
0.864
|
1.138
|
| Expected Upside |
—
|
—
|
AI Committee View
Current Innellis committee reasoning for TEVA versus WST.
WST leads by 19 points.
WST scores 74/100 (Buy) versus TEVA at 55/100 (Watch).
TEVA Committee View
50% agreement
6 analysts
The committee is genuinely divided. News Analyst sees a compelling case — news sentiment is positive (+0.63 across 21 articles, 14d). Value Analyst remains cautious — p/e of 57.5 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
- P/E of 57.5 is expensive by classic value standards — Value
- Price-to-book of 4.9x prices in significant intangible value — Value
- Debt-to-equity of 2.12 adds balance-sheet risk to the value case — Value
WST Committee View
100% agreement
5 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is 2 existing position pair(s) are highly correlated already. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical